NCT00952991View on ClinicalTrials.gov

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
DRUG

LAF237 = vildagliptin

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Mayo Clinic

OTHER